Otsuka Pharmaceutical Co., Ltd., commonly referred to as Otsuka, is a leading global healthcare company headquartered in Japan. Established in 1964, Otsuka has made significant strides in the pharmaceutical and nutraceutical industries, focusing on innovative solutions for mental health, oncology, and general healthcare. With a strong presence in regions such as North America, Europe, and Asia, Otsuka is renowned for its unique products, including the antipsychotic medication Abilify and the hydration solution Pocari Sweat. The company’s commitment to research and development has positioned it as a pioneer in addressing unmet medical needs. Otsuka's dedication to innovation and patient care has earned it a notable reputation in the global market, making it a key player in the pharmaceutical landscape.
How does Otsuka Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Otsuka Pharmaceutical's score of 72 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Otsuka Pharmaceutical reported total carbon emissions of approximately 776,000,000 kg CO2e, comprising 109,739,000 kg CO2e from Scope 1, 1,395,000 kg CO2e from Scope 2, and 664,646,000 kg CO2e from Scope 3 emissions. This reflects a commitment to transparency in their emissions reporting across all scopes. The company has set a long-term goal to achieve "Net Zero" emissions by 2050, as part of its 2050 Environmental Vision. This initiative aims to reduce the total environmental impact of its business activities to zero. To support this vision, Otsuka is implementing an integrated energy service structure under a retail electricity provider model, which is expected to enhance energy efficiency and sustainability. In previous years, Otsuka's emissions have shown fluctuations, with total emissions of approximately 763,050,000 kg CO2e in 2021 and 785,684,000 kg CO2e in 2020. The company continues to focus on reducing its carbon footprint and enhancing its sustainability practices across all operations.
Access structured emissions data, company-specific emission factors, and source documents
2011 | 2012 | 2017 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|
Scope 1 | 285,728,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 116,816,000 | 000,000,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 3 | 402,544,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Otsuka Pharmaceutical is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.